Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - glucosum - innrennslislyf, lausn - 100 mg/ml

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - glucosum - innrennslislyf, lausn - 200 mg/ml

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - glucosum - innrennslislyf, lausn - 50 mg/ml

Euroopa Liit - islandi - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 18 mg

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 10 mg

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 100 mg

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 25 mg

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 40 mg

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 60 mg